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Objective   To determine the prevalence of the different capsular polysaccharide (CP) and 30 
the major surface-associated non-CP antigen 336 (SP-336) types among S. aureus isolated 31 
from bovine mastitis cases in Australia and India.  32 
Methods   A total of 414 strains (154 from Australia and 260 from India) isolated from 33 
clinical bovine mastitis were included for the study. Mouse antisera raised against CP types 34 
(CP1, CP2, CP5, and CP8) or SP-336 were used in slide agglutination tests and compared to 35 
detection of cap1, cap5 and cap8 gene fragments by PCR.  36 
Results   Serological studies revealed the presence of CP2, CP5, CP8 and SP-336 in 9.1%, 37 
23.4%, 31.8%, and 5.8% of the Australian versus 0.8%, 46.9%, 13.1% and 0% of the Indian 38 
isolates, respectively. By PCR, CP1, CP5 and CP8 accounted for 0%, 26.6% and 32.4% of 39 
the Australian versus 3.9%, 85% and 8.1% of the Indian isolates, respectively.  40 
Conclusions   Both PCR and serological study have demonstrated that CP5 and CP8 are the 41 
predominant capsular types in Australia whereas CP5 is the predominant capsular type in 42 
India. The study has also demonstrated a strong correlation between both the methods of 43 
typing for CP1, CP5, CP8 and non-typeable S. aureus strains. Prevalence of high percentages 44 
of non-typeable isolates in both the countries highlights the importance of continued 45 
investigations on the identification of unique surface-associated polysaccharide antigens 46 
prevalent among S. aureus isolates for the formulation of CP and SP-based vaccines for 47 
bovine mastitis. 48 
---------------------------------------------------------------------------------------------------------------- 49 
Key words   capsular and polysaccharide antigen 336, dairy cattle, mastitis, serology, 50 
molecular typing 51 
Abbreviations    CP, Capsular polysaccharide; SP, Surface polysaccharide; PCR, Polymerase 52 
chain reaction; MSSA, Methicillin sensitive Staphylococcus aureus; AISRF, Australia India 53 
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Strategic Research Fund; MH, Mueller Hinton; ATCC, American type culture collection; 54 
CFU, Colony forming unit; DNA, Deoxyribonucleic acid; UV, Ultra violet; PNAG, Poly-N-55 
acetyl glucosamine; CHIRI, Curtin Health Innovation Research Institute. 56 
 57 
Introduction 58 
  The Australian and Indian dairy industries sustain economic losses estimated to be more 59 
than US$130 million
1
 and US$1200 million
2
, respectively, due to poor udder health, which is 60 
mainly caused by mastitis. Staphylococcus aureus is one of the predominant causative agents 61 






 The current 62 
conservative practice of treating mastitis with antibiotics is not only economically unviable in 63 
the long term, especially for the marginal and small-scale dairy farmers in India, but also 64 
promotes the emergence of strains resistant to antibiotics including methicillin.
10-15
 Given the 65 
recent reports that even MSSA (methicillin-sensitive Staphylococcus aureus ) can become 66 
resistant to certain antimicrobials when presented as biofilms adds another dimension to 67 
bovine mastitis caused even by MSSA.
16-18
 In addition, there is increasing evidence for cross 68 
transmission of virulent S. aureus between dairy cattle and humans
19-23 
with implications for 69 
public health. There is an urgent need for a suitable vaccine against mastitis to reduce the 70 
bacterial load and the probability of successful cross transmission.  71 
 72 
Capsular polysaccharide (CP) is one of the most important virulence factors of S. aureus
24,25
 73 
as it confers resistance to phagocytosis
26
 and prolongs persistence of the pathogen in the 74 
blood stream of the host.
27
 Earlier serological studies suggested the existence of 11 different 75 
serotypes of CP.
28,29
 However, a more recent study
30
 indicated that there were only four types 76 
(CP 1, 2, 5 and 8), all the other reported types representing mutated versions. Most human 77 
clinical isolates have been reported to express either CP5 or CP8, accounting for ~80% of the 78 
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total isolates from all sources.
31,26
 The rest were designated non-typeable S. aureus; most of 79 
these strains were reported to possess a unique surface polysaccharide antigen 336
29
, which 80 
contained polyribitol-phosphate-N-acetylglucosamine, a component of cell wall teichoic 81 
acid.
26
  82 
 83 
Knowledge of the type of CPs of the S. sureus isolates circulating on farms is essential in the 84 
formulation of the CP-based conjugate vaccine formulations because of their better 85 
immunogencity due to T cell-dependence than the capsular polysaccharide formulations 86 
which are T cell-independent
32-34
. Since the prevalence of CPs may be different in different 87 
countries
28,31,35-38
, conjugate vaccine formulations specific for each farm or a broad-spectrum 88 
vaccine representing all the capsular types, surface-associated immune evasion molecules
39
, 89 
conjugated to the most significant homologous or heterologous colonisation protein 90 
antigen(s), may be need to be formulated.  91 
Because of the distribution of the different capsular types of S. aureus around the world may 92 
differ
35-38
, it is important to know their prevalence in Australia and India used in this study as 93 
model developing country with backyard farming practices, in order to rationally select 94 
suitable vaccine candidates as vaccine candidates. However, there are no reports on the 95 
prevalence of different CP types of S. aureus causing bovine mastitis either in Australia or in 96 
India. Hence the objective of this study was to determine the distribution of different capsular 97 
phenotypes among the Australian and the Indian S. aureus strains isolated from clinical 98 
bovine mastitis cases.  99 
 100 
Material and Methods 101 
S. aureus isolates 102 
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One hundred and fifty four (154) fully characterised S. aureus strains of Australian origin 103 
isolated from clinical cases of mastitis in cows in Victoria and Queensland were generously 104 
donated by Professor Margaret Deighton, (RMIT University), Dr. Sharon de Wet 105 
(Queensland Biosecurity laboratory) and Dr. Justine Gibson (University of Queensland). In 106 
India, 260 strains were isolated from clinical cases of mastitis in cows from different parts of 107 
the country (Karnataka, Andhra Pradesh, Goa, Uttar Pradesh and Gujarat)  and identified as 108 
S. aureus using the standard biochemical tests.
40
 Reference strains representing CP types 1 109 
(strain M), 2 (strain Smith diffuse), 5 (strain Newman), 8 (USA 400 MW2) and a non-110 
capsulated strain (LAC, USA 300) were donated by Professor Gerald Pier (Harvard Medical 111 
School, Boston, USA). S. aureus ATCC-55804 designated as serotype 336 was purchased 112 
from ATCC, USA. These isolates were grown on Mueller Hinton (MH) agar and subcultured 113 
in nutrient broth supplemented with 1% glucose and stored on cryobeads (Blackaby 114 
Diagnostics) or as glycerol (15%) broth stocks at -80°C. 115 
 116 
Production of antisera for serological typing 117 
Six week-old specific pathogen-free Quackenbush Swiss line 5 mice obtained from the 118 
Animal Resources Centre, Perth, Western Australia were and used for production of CP and 119 
antigen 336-specific antisera. All animal experiments were carried out with the approval of 120 
Curtin University’s Animal Ethics Committee.  121 
 122 
Preparation of the different anti-CP type 1, 2, 5, 8 and SP-336 antisera was carried out 123 
according to Fournier et al. (1984)
41
. Briefly, bacterial suspensions of S. aureus CP types-1, 124 
2, 5, 8 and SP-336 grown for 18 h on MH agar plated at 37
o
C and killed with 3% 125 
formalinised PBS followed by washing with PBS (5X). Mice were immunized every week 126 









 CFU in 0.2mL respectively, were administered by the intraperitoneal 128 
route.. For the fourth and fifth doses, the bacterin was mixed with equal proportion with 129 





CFU, respectively, and administered subcutaneously one week apart. Mice were blood 131 
samples for collection of sera. The CP-/SP-specific antisera were cross-absorbed with non-132 
capsulated S. aureus strain LAC, USA 300, followed by cross-absorption with the 133 
heterologous CP types CP1, CP2, CP5, and CP8 depending upon the desired CP specificity. 134 
For SP-336 serum, the same method was followed, initially cross absorbed with non-135 
capsulated LAC USA followed by cross absorption with CP 1, 2 5 and 8. 136 
 137 
CP serotyping of S. aureus isolates 138 
Slide agglutination test was performed to determine the serotype of the strains.
26
 Each strain 139 
was grown overnight on MH agar and a single colony was resuspended in a drop of 0.9% 140 
normal saline in a clean glass slide. A drop of serum was added to it and observed for 141 
agglutination in less than 20 sec. The strains, which showed no agglutination against any of 142 
the four sera, were further tested for agglutination using anti-SP336 serum. Strains found 143 
negative with all the five specific sera were considered as non-typeable. 144 
 145 
CP genotyping of S. aureus isolates  146 
Genomic DNA was extracted from S. aureus using a kit (Geneworks, SA, Aust or Real 147 
Biotech Corp., Taiwan) Detection of the presence of cap1, cap2, cap5 and cap8 loci in all the 148 
strains was done by Polymerase Chain Reaction (PCR). The primers used for typing cap1 are 149 
5’-AGG TCT GCT AAT TAG TGC AA-3’ (forward) and 5’-GAA CCC AGT ACA GGT 150 
ATC ACC A-3’ (reverse) with an expected product size of 550 bp and for cap2 are 5’-AGC 151 
AAT CTT CGG TTA TTG CCG GTG-3’ (forward) and 5’-ATG ACG GTA AGG CAT 152 
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CAA GGT CG-3’ (reverse) with an expected amplicon size (non-specific). The PCR cycling 153 
parameters for both cap1 and cap2 were: denaturation at 94
o
C for 5 min followed by 94
o
C for 154 
30 sec, Tm at 57
o
C (cap1) or 60
o
C (cap2) for 30 sec, 72
o
C for 60 sec with 25-30 cycles and 155 
final extension at 72
o
C for 5 min.  156 
 157 
The primers used for typing cap5 and cap8 were 5’- ATG ACG ATG AGG ATA GCG-3’ 158 
(forward) and 5’- CTC GGA TAA CAC CTG TTG C-3’ (reverse) for cap5 and 5’- ATG 159 
ACG ATG AGG ATA GCG-3’ (forward) and 5’- CAC CTA ACA TAA GGC AAG-3’ 160 
(reverse) for cap8, respectively.
42
 The expected band sizes were 881 bp and 1148 bp for cap5 161 
and cap8, respectively.  Thermal cycling conditions were denaturation at 95
o
C for 5 min, 162 
95
o
C for 30 sec, Tm of 55
o
C (cap5) or 52
o
C (cap8) for 30 sec, 72
o
C for 5 min with 25-30 163 
cycles and the final extension at 72
o
C for 5 min.  164 
 165 
The PCR products were analysed by agarose gel (1.5%) electrophoresis, Midori Green 166 
staining and UV trans-illumination. The positive controls included strains M, Smith Diffuse, 167 
Newman and USA 400 for cap1, cap2, cap5 and cap8, respectively, and LAC, USA 300 was 168 
used as negative control. 169 
 170 
Statistical analysis 171 
Correlation coefficients, represented as Pearson r values, between the serological with the 172 
genotyping method, for CP1, CP5, CP8 positive and non-typeable S. aureus strains, were 173 
determined using Microsoft Excel, Windows 10. 174 
 175 
Results 176 
Prevalence of capsular or antigen 336 types in bovine S. aureus isolates  177 
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Genotyping of 154 Australian S. aureus isolates revealed that 41 (26.62%) and 50 (32.47%) 178 
strains were positive for cap5 and cap8 (Table1). None of the isolates were positive for the 179 
cap1 locus. The primers for the cap2 locus exhibited cross-reactivity with all the other three 180 
CP types producing amplicons of 700-800 bp (data not shown). A total of 63 (40.91%) S. 181 
aureus strains, which carried none of the three loci (cap5, cap8 or cap1), were declared as 182 
negative by PCR (Table1).   183 
 184 
Serotyping of 154 S. aureus isolates using CP-specific sera (Table 1) confirmed the 185 
genotyping results; 36 (23.4%) and 49 (31.8%) of the isolates revealed the presence of CP5 186 
and CP8, respectively, whereas none was positive for CP1. However, 14 (9.1%) strains were 187 
positive for CP2. The strains that were not agglutinated by any of the CP-specific sera were 188 
subjected to slide agglutination using anti-SP336 antiserum. Nine (5.8%) isolates were 189 
positive for SP-336 and the remaining 46 (29.9%) were declared as non-typeable.  190 
 191 
Among the 260 Indian isolates, 10 (3.9%), 221 (85%) and 21(8.1%) were positive for cap1, 192 
cap5 and cap8 loci, whereas the 8 (3.08%) negative for all the three loci were considered as 193 
non-capsulated in genotyping. Serotyping revealed that 2 (0.8%), 122 (46.9%) and 34 194 
(13.1%) isolates were positive for CP1, CP5 and CP8, respectively.  None of the remaining 195 
isolates was positive for either CP2 or SP-336, indicating that 102 (39.2%) isolates were non-196 
typeable (Table 1). 197 
 198 
The correlation coefficient (r) between the serological and genotyping methods for detection 199 
of CP types 1, 5 and 8, and the non-typeable S. aureus isolates, was determined to be 0.97 200 




Discussion and conclusions 203 
Given the role of surface-associated polysaccharides in the virulence of S. aureus, 204 
epidemiological investigations on the distribution of capsular and surface polysaccharide 205 
types among S. aureus isolates is important for rational design of a vaccine formulation 206 
against infection with S. aureus. Studies on human S. aureus capsular types have reported 207 
that 75-80% of all the isolates produce either CP5 or CP8.
38,43,44 
 However, the prevalence of 208 
the CP serotypes (CP5 and 8) among the S. aureus strains isolated from cow’s milk ranges 209 




 reported that CP typing was superior 210 
to bacteriophage typing whereas another study
48
 had reported the capsular typing was less 211 
sensitive than genome typing yielding 26 different S. aureus types. Another study analyzed 212 
the genetic diversity of S. aureus isolated from subclinical mastitis cases in cows and 213 
reported the presence of 16 types and 24 subtypes
46
. However, no information on their 214 
correlation with the different capsular types was reported.   215 
 216 
The present study revealed that 64.3% of Australian bovine mastitis-associated S. aureus 217 
strains expressed capsule, of which, CP8 was predominant (31.8%), followed closely by CP5 218 
(23.4%). A total of 60.8% of the Indian isolates expressed capsule, of which CP5 type was 219 
dominant (46.9%). In addition, 5.8% (nine of 154) of the Australian isolates were positive for 220 
SP-336, whereas none of the Indian isolates were positive for this antigen. The fact that about 221 
40% of the Indian isolates were non-typeable suggests the possible existence of more diverse 222 
S. aureus populations in India than in Australia where about 30% of the isolates were non-223 
typeable.  These differences could be due to a multitude of factors including breed, husbandry 224 
and therapeutic practices, human-animal interface and various other environmental factors 225 
that are different between the two countries.  However, it is difficult to draw any conclusions 226 
on whether S. aureus is transmitted between humans and animals in India because of a wide 227 
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variation in the distribution of the capsular phenotypes ranging from 21% to 63% for CP5 228 
and 37% to 64% for CP8
47,49,50
. There are no publications on the distribution of CP types of 229 
bovine mastitis-associated S. aureus isolates from Australia, although only one study has 230 
genotypically characterised the CP5 and CP8 of Indian isolates
51
. That study revealed that 231 
60% of the cattle isolates and 20% of the goat isolates carried the cap5 gene, and 20% and 232 
30% of cattle and goat isolates, respectively, carried the cap8 gene.
51
 However, only 20 S. 233 
aureus isolates were used in that study whereas 260 isolates from different parts of India 234 
were used in this study, projecting a more reliable distribution of CP types in India. 235 
 236 
Very few studies have compared the performance of genotyping versus serology in the typing 237 
of S. aureus isolates. One study compared the prevalence of CP5 and CP8 types of 238 
Staphylococcus aureus among isolates from intramammary infections in Argentine dairy 239 
cattle and found 64% of the isolates as genotypes cap5 or cap8 and 50% as CP5 or 8 240 
serologically
52
. In contrast, one study with human isolates, there was 100% correlation 241 
between capsular genotypes and phenotypes for CP5 and CP8.
53
  In this study, five (3.3%) 242 
Australian bovine mastitis-associated strains carrying cap5 and one strain (0.7%) carrying 243 
cap8 were negative by agglutination. More strikingly, 99 (38.1%) cap5 positive and eight 244 
(3.1%) cap1 positive Indian S. aureus strains did not express respective capsular phenotype 245 
when judged by serological typing. In contrast, 13 (5%) Indian strains that were positive for 246 
CP8 by serology were negative by genotyping.  The discordance between genotyping and 247 
phenotyping may be attributable to non-expression of respective capsule-encoding genes, 248 
possibly due to mutations
30







 It is thus clear from this study that any surface-associated polysaccharide antigens-based 252 
vaccine formulation should not only include CP5 and CP8 types but also other capsular types, 253 
with or without antigen 336 or poly-N-acetyl glucosamine (PNAG), reported to be present in 254 
all S. aureus isolates
56
 for prevention of clinical bovine mastitis caused by S. aureus. The 255 
prevalence of 29.87% and 39.23% of non-typeable S. aureus strains in Australia and India, 256 
respectively, also highlights the need to explore the existence of other surface-associated 257 
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Table 1  444 
Prevalence of capsular/surface polysaccharide phenotypes versus genotypes of S. aureus 445 





 = Slide agglutination test; 
c
PDW= Primers did not work, 
d
PNA= Primers not available 448 
Correlation coefficient (r) between SAT and PCR method for detection of CP1, CP5,CP8 and non-typeable S. aureus strains are 0.97 449 



























Detection of capsular type by PCR Typing by PCR 




































India 260 2 
(0.8) 
0 122 
(46.9) 
34 
(13.1) 
0 102 
(39.2) 
10 
(3.9) 
PDW
c
 221 
(85) 
21 
(8.1) 
PNA
d
 
 
8 
(3.1) 
